Regeneron (REGN) Gets a Hold from Scotiabank
Scotiabank analyst Louise Chen maintained a Hold rating on Regeneron (REGN) with a $770 price target. Regeneron also received a Hold from Leerink Partners and a Buy from BMO Capital. The company reported Q2 revenue of $4.29B and net profit of $1.3B, up from $3.68B and $1.39B last year.
How this was made
The 30-second read
Why it matters
Analyst rating change adds a new valuation perspective for traders.
Market read
The rating update provides fresh guidance for short‑term positioning in REGN.
What to watch
Upcoming pipeline data and long‑term growth prospects are not addressed in the rating.
Background
Regeneron recently reported Q2 earnings with revenue growth but a slight profit decline.
Ticker impact
Scotiabank analyst Louise Chen maintained a Hold rating on Regeneron and set a $770 price target today.
Potential slight downside or flat price action as investors reassess valuation.
Hold rating signals no strong conviction; price target below prior expectations could lead to modest sell pressure.
Market effects
Healthcare sector may see slight re‑rating pressure as peers receive similar analyst coverage.
U.S. biotech stocks could experience minor ripple effects.
Limited to investors tracking Regeneron and related biotech equities.
Counterpoint
Some investors may view the Hold as a buying opportunity if they disagree with the lower target.
Key entities
- AnalystLouise Chen
Scotiabank healthcare analyst who issued the Hold rating.
